The FDA approved the generic version, Wixela Inhub (fluticasone-salmeterol; Viatris), as the first generic maintenance inhaler for asthma and chronic obstructive pulmonary disease (COPD) in 2019 ...

About 69% of hospitalized COPD patients misused inhalers, 66% made critical errors during inhaler use, and 14% had insufficient PIF. An average of 1.4 and 1.3 and critical errors for every inhaler ...

That spurred three of the four leading inhaler companies (GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim) to announce in March 2024, that they would cap out-of-pocket costs at $35 per inhaler.

Smart inhaler company Adherium announced last week that it has received 510(k) clearance for over-the-counter sales of its inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler, called ...

Another OTC Alternative: Asthmanefrin Asthmanefrin (racepinephrine hydrochloride) is not used with an inhaler but is sold as a liquid solution packaged in single doses. It is used with a special ...

Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation (hazard ratio, 1.07; 95 percent ...

The researchers found that the incidence of a first moderate or severe COPD exacerbation was higher in patients who received budesonide-glycopyrrolate-formoterol (hazard ratio [HR], 1.09; [95% CI ...

The FDA approved United Kingdom-based GlaxoSmithKline’s Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease. The inhaler, developed with ...

A 2017 study looked at around 2,600 Medicare Part D and Medicare Advantage plans to determine the average out-of-pocket costs for COPD inhalers. Depending on the inhaler type, costs ranged from ...

Baldomero AK, Kunisaki KM, Wendt CH, et al. Guideline-discordant inhaler regimens after COPD hospitalization: associations with rurality, drive time to care, and fragmented care - a United States ...

Crude incidence of first moderate-to-severe COPD exacerbation was 435 and 410 events per 1,000 person-years for the branded and generic groups, respectively, the bulk of which were moderate cases ...

The European Medicines Agency has approved Almirall’s aclidinium bromide inhaler (Eklira Genuair) for twice daily use as a means of relieving symptoms in adult patients with COPD. The drug component, ...